Last reviewed 2026-05-22 · How we verify

WGc-0201 injection

West China Hospital · Phase 1 active Biologic ✓ Verified May 2026 Quality 0/100

WGc-0201 injection is a Biologic drug developed by West China Hospital. It is currently in Phase 1 development.

WGc-0201 injection is being studied in a clinical trial for the treatment of Hepatocellular Carcinoma (HCC) with a high risk of recurrence and metastasis after radical therapy. The trial is a Phase I study combining WGc-0201 injection with Tislelizumab.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	WGc-0201 injection
Sponsor	West China Hospital
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical Therapy (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

WGc-0201 injection CI brief — competitive landscape report
WGc-0201 injection updates RSS · CI watch RSS
West China Hospital portfolio CI

Frequently asked questions about WGc-0201 injection

What is WGc-0201 injection?

WGc-0201 injection is a Biologic drug developed by West China Hospital.

Who makes WGc-0201 injection?

WGc-0201 injection is developed by West China Hospital (see full West China Hospital pipeline at /company/west-china-hospital).

What development phase is WGc-0201 injection in?

WGc-0201 injection is in Phase 1.

Manufacturer: West China Hospital — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing